WHO lists mpox vaccine by Japan's KM Biologics for emergency use
The World Health Organization listed KM Biologics' mpox vaccine for emergency use on Tuesday, making it the second shot to get the approval of the global health agency. It declared mpox a global public health emergency for the second time in two years in August after a new variant of the virus,
World Health Organization approves emergency use of second mpox vaccine
The World Health Organization Tuesday granted emergency use authorization for the second mpox vaccine. The LC16m8 vaccine from Japan's KM Biologics is the second since WHO declared mpox a health emergency in August.
WHO approves Japanese pharmaceutical company's mpox vaccine
The listing from the World Health Organization paves the way for countries worldwide to quickly approve and import the vaccine for distribution.
WHO OKs 2nd mpox vax from Japan
The World Health Organization (WHO) has granted approval to LC16m8 mpox vaccine, produced by a Japanese pharmaceutical firm. It is the second vaccine to be approved by the world health body after it declared mpox a public health emergency of international concern (PHEIC) in August.
WHO OKs emergency use of Japanese mpox vaccine
The World Health Organization has granted emergency use of a Japanese mpox vaccine, its second approval of a product to inoculate against the infectious disease, to combat a recent outbreak mainly in Africa.
WHO approves Japanese mpox vaccine for emergency use
The World Health Organisation (WHO) has granted emergency use listing (EUL) for the LC16m8 mpox vaccine. This would be the
First mpox vaccine for children approved by WHO to fight virus outbreak
The vaccine is the second to be approved by the UN agency and the first approved for children aged one and older. View on euronews
Health Matters: WHO approves first mpox vaccine for kids
The World Health Organization has authorized the first m-pox vaccine for children. It's a decision experts hope will help make immunizations more widely available to one of the hardest-hit populations during the ongoing outbreaks of the disease in Congo and elsewhere in Africa.
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...
No, Japan didn’t name COVID-19 vaccine ‘most deadly drug in history’ | Fact check
There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.
NHK4d
WHO permits emergency use of Japan-made mpox vaccine
The World Health Organization has permitted emergency use of a Japanese vaccine to inoculate against mpox, previously known ...
FarmOnline12d
Lumpy skin disease in Japan could be a game changer for mRNA vaccine work
The detection of lumpy skin disease in Japan could be the game changer that prompts far greater financial investment into ...